Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Under Consent Decree, J&J Delays Full Return Of Recalled OTCs Until 2012

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson pushes back to 2012 the target for returning its full slate of recalled OTC drugs to market as it adjusts to operating under a consent decree with FDA and the Department of Justice.
Advertisement

Related Content

J&J Promotes Preventive Care, Wellness In US Health Debate
J&J Promotes Preventive Care, Wellness In US Health Debate
J&J’s Caruso Pitches OTC Comeback To Analysts
J&J Consumer Recaptures Growth, Plans To Restore Most OTCs By Mid-2012
M&A Market Heating Up As Economy “Stagnates,” C&D's Craigie Says
Acquisition Market Heating Up As Economy “Stagnates” – C&D's Craigie
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
J&J Washes Hands Of Purell As GOJO Eyes Consumer Segment Growth

Topics

Advertisement
UsernamePublicRestriction

Register

PS105012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel